A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

245

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2030

Study Completion Date

May 31, 2030

Conditions

Advanced Solid Cancers

Interventions

DRUG

BNT329

Intravenous (IV) infusion

DRUG

CA19-9-targeting monoclonal antibody

Monoclonal antibody